The following are relevant articles that provide more in-depth information on mTOR and its role in cancer. This list of publications will be updated on an ongoing basis as information becomes available.
Dancey JE. Therapeutic Targets: mTOR and Related Pathways. Cancer Biol Ther. 2006. 5:1065-1073
A preclinical and clinical overview of mTOR in human cancer.
Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res. 2007 13:3109-31140
Highlights recent advances in our understanding of mTOR and the implications of these findings for the clinical application of mTOR inhibitors in cancer patients.
Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424-430.
Reviews recent findings which highlight how RAS and mTOR pathways contribute to tumorigenesis and discusses addressing issues faced in designing rational therapies for cancer patients.
Wullschleger S, Loewith R, Hall, MN. TOR Signaling in Growth and Metabolism. Cell. 2006 124:471-476
Article reviews the mammalian TOR complexes and the signaling branches they mediate suggesting that inhibitors of mammalian TOR may be useful in the treatment of cancer.
Klatte T, Seligson DB, Riggs SB, et al. Hypoxia-inducible factor 1α in clear cell renal cell carcinoma. Clin Cancer Res. 2007;13(24):7388-7393.
HIF-1α plays an important role in the adaptation of renal cell carcinoma to hypoxic conditions and is an independent prognostic factor in renal cell carcinoma.
Park SB, Cho K, Lee JH, et al. Unusual manifestations of renal cell carcinoma. Acta Radiol. 2008;
Increased familiarity with imaging features of renal cell carcinomas may help facilitate diagnosis and treatment.
Merseburger AS, Hennenlotter J, Kuehs U, et al. Activation of PI3K is associated with reduced survival in renal cell carcinoma. Urol Int.2008;80(4):372-377.
The EGFR-activated PI3K/PKB/Akt pathway is associated with tumorigenesis and progression in renal cell carcinoma, particularly in association with low PTEN expression.
Furge KA, Dykema K, Petillo D, et al. Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma. Can Urol Assoc J. 2007;1(2)(suppl):S21-7.
High-throughput gene-expression profiling technology may provide a better understanding of the complex biology of renal cell carcinoma.
Lim DL, Ko R, Pautler SE. Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists. Can Urol Assoc J. 2007;1(2)(suppl):S13-20.
Awareness of the cellular mechanisms underlying renal cell carcinoma can provide clinicians with valuable insights into the use of targeted therapies.
Nyhan MJ, O’Sullivan GC, McKenna SL. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. Biochem Soc Trans. 2008;36(3):472-478.
The VHL gene protects against carcinogenesis by degrading HIF-α and by inhibiting angiogenesis, cellular invasion, and the formation of renal cysts.
Mancini V, Battaglia M, Ditonno P, et al. Current insights in renal cell cancer pathology. Urol Oncol. 2008;26(3):225-238.
New tumor-associated antigens and molecules can now be identified at the protein level using proteomics, providing a major opportunity for screening and finding novel targets that are the basis of new emerging therapies for renal cell carcinoma.
Furniss D, Harnden P, Ali N, et al; On behalf of the National Cancer Research Institute Renal Clinical Studies Group. Prognostic factors for renal cell carcinoma. Cancer Treat Rev. 2008;34(5):407-426.
There are a number of scoring systems used evaluate patients with renal cell carcinoma; however, most rely on retrospective data and may not accurately reflect prognosis in the era of targeted therapies.
Tunuguntla HSGR, Jorda M. Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol. 2008;179(6):2096-2102.
Several molecular markers appear to hold promise for refining the prognosis and prediction of localized, advanced, or metastatic renal cell carcinoma.
